This clinical trial focuses on studying migraine, a common type of headache that can cause severe pain and other symptoms. The study will test two treatments: Sumatriptan and Rimegepant. These medications are used to relieve migraine symptoms. The trial will also involve the use of nitroglycerin, a substance that can induce headaches, to better understand how these treatments work during a migraine attack.
The purpose of the study is to observe changes in certain biochemical markers in the blood and saliva during a migraine attack and after treatment with Sumatriptan and Rimegepant. Participants will receive either Sumatriptan or Rimegepant during the trial, and their response to these treatments will be monitored. The study will help determine how these medications affect the levels of specific markers in the body, which could provide insights into their effectiveness in treating migraines.
Participants will be involved in a randomized cross-over trial, meaning they will receive both treatments at different times. The study will track the evolution of biochemical markers at four different points: before the migraine starts, at the beginning of the migraine, at the peak of the migraine, and two hours after treatment. This approach will help researchers understand the relationship between these markers and the response to migraine treatments.
Spain 
